SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:DiVA.org:liu-51402"
 

Search: onr:"swepub:oai:DiVA.org:liu-51402" > Early abciximab adm...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • Rakowski, TomaszJagiellonian University (author)

Early abciximab administration before transfer for primary percutaneous coronary interventions for ST-elevation myocardial infarction reduces 1-year mortality in patients with high-risk profile. Results from EUROTRANSFER Registry

  • Article/chapterEnglish2009

Publisher, publication year, extent ...

  • Elsevier BV,2009
  • printrdacarrier

Numbers

  • LIBRIS-ID:oai:DiVA.org:liu-51402
  • https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-51402URI
  • https://doi.org/10.1016/j.ahj.2009.08.008DOI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • Background There are conflicting data on the clinical benefit from early administration of abciximab from a large randomized trial and a registry. However, both sources suggest that a benefit may depend on the baseline risk profile of the patients. We evaluated the role of early abciximab administration in patients with ST-segment-elevation myocardial infarction (STEMI) referred for primary percutaneous coronary intervention stratified by the STEMI Thrombolysis In Myocardial Infarction (TIMI) risk score. Methods A total of 1,650 patients were enrolled into the EUROTRANSFER Registry. One thousand eighty-six patients received abciximab (66%). Abciximab was administered early in 727 patients (EA) and late in 359 patients (LA). We used the TIMI risk score for risk stratification. Patients with scores 3 constituted the high-risk group of 616 patients (56.7%), whereas 470 patients formed the low-risk cohort. Factoring in the timing of the abciximab administration resulted in 4 groups of patients who were compared for mortality at 1 year: EA/high-risk (n = 413); LA/high-risk (n = 203); EA/low-risk (n = 3 14); LA/low-risk (n = 156). Baseline difference was accounted for by means of propensity score. Results In high-risk patients, 1-year mortality was significantly lower with early abcximab compared to late administration (8.7% vs 15.8%; odds ratio 0.51, CI 0.31-0.85, P = .01). In multivariable Cox regression analysis, both early abciximab administration and patients risk profile (TIMI score :3) were identified as independent predictors of 1-year mortality. Conclusions Early abciximab administration before transfer for percutaneous coronary intervention in STEMI shows lower mortality at 1-year follow-up. This effect is confined to patients with higher risk profile as defined by TIMI risk score andgt;= 3.

Subject headings and genre

  • MEDICINE
  • MEDICIN

Added entries (persons, corporate bodies, meetings, titles ...)

  • Siudak, ZbigniewJagiellonian University (author)
  • Dziewierz, ArturJagiellonian University (author)
  • Birkemeyer, RalfSchwarzwald Baar Klinikum Villingen Schwenningen (author)
  • Legutko, JacekJagiellonian University (author)
  • Mielecki, WaldemarJagiellonian University (author)
  • Depukat, RafalJagiellonian University (author)
  • Janzon, MagnusÖstergötlands Läns Landsting,Linköpings universitet,Kardiologi,Hälsouniversitetet,Kardiologiska kliniken(Swepub:liu)magja75 (author)
  • Stefaniak, JustynaKrakow Cardiovasc Research Institute (author)
  • Zmudka, KrzysztofJagiellonian University (author)
  • Dubiel, Jacek SJagiellonian University (author)
  • Partyka, LukaszKrakow Cardiovasc Research Institute (author)
  • Dudek, DariuszJagiellonian University (author)
  • Jagiellonian UniversitySchwarzwald Baar Klinikum Villingen Schwenningen (creator_code:org_t)

Related titles

  • In:AMERICAN HEART JOURNAL: Elsevier BV158:4, s. 569-5750002-8703

Internet link

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view